Related Experiment Video
Updated: Jul 17, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases
1Division of Rheumatology, University of Southern California, 2011 Zonal Ave. HMR 711, Los Angeles, CA 90033, USA. stohl@usc.edu
Abstract:
B lymphocyte stimulator (BLyS) is a vital B cell survival factor. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). Treatment with BLyS antagonists of mice with established SLE ameliorates disease progression and enhances survival. Moreover, similar treatment of mice with inflammatory arthritis ameliorates the ongoing inflammation and subsequent joint destruction. In humans, BLyS overexpression is common in patients with several rheumatic diseases, including SLE, rheumatoid arthritis (RA), Sjögren's syndrome, scleroderma, Wegener's granulomatosis, and ANCA-associated vasculitis. Results from phase-II clinical trials with a BLyS antagonist in human SLE and RA have shown the antagonist to have biological and clinical activity along with a favorable safety profile. These features collectively point to BLyS as an attractive therapeutic target in human rheumatic diseases.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
